- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01472575
Impact of Rotavirus Vaccine Introduction for South Australian Children
An Observational, Cross-sectional, Cohort Study to Assess the Impact of the Rotavirus Vaccine Introduction on Severe Gastroenteritis in South Australian Children
This project aims to assess the impact of rotavirus vaccine introduction on severe gastroenteritis in South Australian children. Prevalence of rotavirus coded hospitalisations and all-cause gastroenteritis hospitalisations will be compared for a two year period prior to introduction of the vaccine and a two year period following introduction of the vaccine. Severity of rotavirus coded admissions during the periods will also be assessed.
Hypotheses:
- Introduction of the rotavirus vaccine will result in an 80% reduction in hospitalisations for rotavirus positive gastroenteritis (ICD code A0.80) in children less than two years of age.
- Introduction of rotavirus vaccine will result in an 80% reduction in Paediatric Emergency presentations for rotavirus positive gastroenteritis in children under two years of age.
- Introduction of the rotavirus vaccine will result in a 50% reduction in hospitalisations for all cause gastroenteritis (ICD codes A0.00-A0.90) in children less than two years of age.
- Introduction of the rotavirus vaccine will result in a 50% reduction in Paediatric Emergency presentations for all cause gastroenteritis in children less than two years of age.
- Introduction of rotavirus vaccine will result in a reduction in hospitalisation and Paediatric Emergency presentations in children aged four and five years with rotavirus positive gastroenteritis (unvaccinated cohort).
- There will be no difference in severity of disease as scored by the Vesikari and/or clark severity score prior to and post introduction of rotavirus vaccine
Study Overview
Status
Detailed Description
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
South Australia
-
North Adelaide, South Australia, Australia, 5006
- Women's and Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
males and females aged 0-less than 6 years of age admitted to SA hospital with ICD10-AM separation codes consistent with rotaviral infection or gastroenteritis of any cause.
- for severity component, admissions to the Women's and Children's Hospital will be examined.
Description
Inclusion Criteria:
- males and females aged 0-less than 6 years of age admitted to SA hospital with ICD10-AM separation codes consistent with rotaviral infection or gastroenteritis of any cause.
- for severity component, only admissions to the Women's and Children's Hospital will be examined
Exclusion Criteria:
- nosocomial rotaviral infections (defined as onset >48 hours post admission date) will be reported separately in the severity analysis
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Pre- rotavirus vaccination introduction
Children aged 0-less than 6 years of age admitted to hospital in South Australia with ICD10-AM separation codes consistent with rotaviral infection or gastroenteritis of any cause during the period 01May2005-30Apr2007 (pre vaccine introduction)
|
post rotavirus vaccine introduction
Children aged 0-less than 6 years of age admitted to hospital in South Australia with ICD10-AM separation codes consistent with rotaviral infection or gastroenteritis of any cause during the period 01May2009-30Apr2011 (post vaccine introduction)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in prevalence of rotavirus coded hospital admissions before and after introduction of rotavirus vaccination
Time Frame: 2 years prior to vaccine introduction (01May2005-30Apr2007) and 2 years post vaccine introduction (01May2009-30Apr2011)
|
2 years prior to vaccine introduction (01May2005-30Apr2007) and 2 years post vaccine introduction (01May2009-30Apr2011)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in prevalence of all-cause gastroenteritis coded hospital admissions before and after rotavirus vaccination introduction
Time Frame: 2 years prior to vaccine introduction (01May2005-30Apr2007) and 2 years post vaccine introduction (01May2009-30Apr2011)
|
2 years prior to vaccine introduction (01May2005-30Apr2007) and 2 years post vaccine introduction (01May2009-30Apr2011)
|
Change in proportion of admissions scored as severe (scored by severity index) for rotavirus coded hospital admissions before and after introduction of rotavirus vaccination
Time Frame: 2 years prior to vaccine introduction (01May2005-30Apr2007) and 2 years post vaccine introduction (01May2009-30Apr2011)
|
2 years prior to vaccine introduction (01May2005-30Apr2007) and 2 years post vaccine introduction (01May2009-30Apr2011)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Helen S Marshall, MBBS MD MPH, Women's and Children's Health Network
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 38070 (Registry Identifier: DAIDS-ES Registry Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastroenteritis
-
GlaxoSmithKlineCompletedRotavirus Gastroenteritis | Nosocomial Rotavirus Gastroenteritis
-
National Institute of Allergy and Infectious Diseases...Completed
-
Merck Sharp & Dohme LLCCompletedRotavirus Gastroenteritis
-
VaxartCompletedNorovirus GastroenteritisUnited States
-
VaxartCompletedNorovirus GastroenteritisUnited States
-
National Institute of Allergy and Infectious Diseases...WithdrawnGastroenteritis NorovirusUnited States
-
Merck Sharp & Dohme LLCCompletedRotavirus Gastroenteritis
-
Christian Medical College, Vellore, IndiaKarolinska InstitutetCompletedRotavirus GastroenteritisIndia
-
GlaxoSmithKlineCompletedRotavirus GastroenteritisBrazil